March 8, 2011 โ Nile Therapeutics is pursuing a new indication for cenderitide, formerly CD-NP. The company is looking to develop the drug as an outpatient therapy to be delivered to acutely decompensated heart failure (ADHF) patients continuously for up to 90 days after discharge from the hospital.
March 8, 2011 โ A third-generation bare-metal stent system has received the CE Mark in Europe. Boston Scientificโs Omega platinum chromium coronary stent system is intended to provide interventional cardiologists with improved acute performance in treating patients with coronary artery disease.
March 8, 2011 โ The U.S. Food and Drug Administration (FDA) announced monthly liver enzyme tests are no longer required for those taking Letairis tablets (ambrisentan), made by Gilead Sciences. Ambrisentan is used to treat pulmonary arterial hypertension (PAH).
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 7, 2011 โ Massachusetts General Hospital (MGH) has granted an exclusive license to Santaris Pharma A/S for intellectual property related to the regulation of microRNA for the treatment of cardiovascular disorders.
March 7, 2011 โ Nile Therapeutics will partner with Medtronic to develop natriuretic peptide, cenderitide, formerly CD-NP, for heart failure and renal disease applications.
March 7, 2011 โ A new digital intra-vascular ultrasound (IVUS) catheter has been cleared in Japan. The Eagle Eye Platinum digital IVUS catheter, from Volcano, was introduced at the Percutaneous Coronary Intervention (PCI) Live Demonstration Course in Kurashiki.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 7, 2011 โ Each year between 100,000 and 180,000 Americans die as the result of pulmonary embolism, a complication from blood clots in the lungs. The Vascular Disease Foundation urges Americans, especially women, to learn about the risks of venous blood clots to help prevent these deaths.
March 7, 2011 โ Last week Medtronic Inc. cancelled its five contracts with Novation LLC, one of the largest U.S. group purchasing organizations (GPOs), which previously represented $2 billion. The contracts included reduced price, large group purchases of cardiovascular and orthopedic devices.
March 7, 2011 โ A pilot study testing a system designed to improve acute coronary syndrome (ACS) revascularization has been successfully completed. The study looked at the Picso Impulse System, from Miraco Medical, which is used following primary percutaneous coronary intervention (PCI) to diminish ischemia.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
March 4, 2011 - Occlutech GmbH received a favorable court ruling in Stockholm, Sweden in the ongoing patent litigation case with AGA Medical-St. Jude Medical.
March 4, 2011 โ A new generation of a mobile C-arm has been launched, offering outstanding imaging and a liquid cooling system to allow use over an almost unlimited period of time. The Vision RFD mobile C-arm, from Ziehm, is an alternative to fixed installations in hybrid operating rooms (ORs), especially for hospitals with space and budgetary constraints.
Boston Scientific has completed its acquisition of Atritech. The completion of the transaction follows the signing of a definitive merger agreement announced on Jan. 19, 2011.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
March 4, 2011 โ The U.S. Food and Drug Administration (FDA) recently cleared two new magnetic resonance (MR) systems. Approximately 180 Optima MR360 1.5 Tesla and Brivo MR355 1.5 Tesla scanners, from GE Healthcare, have been ordered by hospitals and imaging centers worldwide.
March 4, 2011 โ According to a retrospective sub-study of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), there is no evidence that implantable cardioverter defibrillator (ICD) benefit varies with time from myocardial infarction (MI) to device implantation. Accordingly, single lead ICD benefit is not restricted to patients with a remote MI (more than 18 months).
March 2, 2011 โ Despite a long-standing requirement for medical device makers to include women in studies they submit to the U.S. Food and Drug Administration (FDA) for approval, only a few include enough or analyze how the devices work specifically in women, according to research in Circulation: Cardiovascular Quality and Outcomes.